East Coast Institute for Research at Baker Gilmour Cardiovascular Institute
- Type
- Non-covered entity
- Where
- Jacksonville, FL
- Received
- $824,350 in 754 records, 2019 to 2024 ($0 general, $824,350 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | Research payment | 98 | $89,481 |
| 2023 | Research payment | 553 | $604,395 |
| 2022 | Research payment | 102 | $128,643 |
| 2019 | Research payment | 1 | $1,830 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | 753 | $822,520 | 2022–2024 |
| SANOFI US SERVICES INC. | 1 | $1,830 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 754 | $824,350 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-09-13 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-09-13 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-09-09 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-09-09 | Alnylam Pharmaceuticals Inc. | $183 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-09-04 | Alnylam Pharmaceuticals Inc. | $1,505 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | $362 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-08-02 | Alnylam Pharmaceuticals Inc. | $162 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-07-17 | Alnylam Pharmaceuticals Inc. | $832 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-06-17 | Alnylam Pharmaceuticals Inc. | $832 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | $14,573 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | $1,090 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | $405 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | $232 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-06-03 | Alnylam Pharmaceuticals Inc. | $109 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-05-17 | Alnylam Pharmaceuticals Inc. | $3,151 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-05-17 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $666 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-26 | Alnylam Pharmaceuticals Inc. | $61 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-22 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-04-22 | Alnylam Pharmaceuticals Inc. | $116 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-04-22 | Alnylam Pharmaceuticals Inc. | $109 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-04-12 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-12 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-04-01 | Alnylam Pharmaceuticals Inc. | $90 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-04-01 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-25 | Alnylam Pharmaceuticals Inc. | $1,421 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-25 | Alnylam Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-25 | Alnylam Pharmaceuticals Inc. | $187 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-11 | Alnylam Pharmaceuticals Inc. | $2,436 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-11 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-11 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-08 | Alnylam Pharmaceuticals Inc. | $1,505 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $3,009 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $2,732 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-03-04 | Alnylam Pharmaceuticals Inc. | $1,121 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-29 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-14 | Alnylam Pharmaceuticals Inc. | $495 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-02-14 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-02-09 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-09 | Alnylam Pharmaceuticals Inc. | $360 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $1,121 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $1,121 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $800 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $230 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-02-02 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-31 | Alnylam Pharmaceuticals Inc. | $30 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-26 | Alnylam Pharmaceuticals Inc. | $2,070 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $800 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-19 | Alnylam Pharmaceuticals Inc. | $122 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $832 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $800 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-12 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-10 | Alnylam Pharmaceuticals Inc. | $122 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-10 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2024-01-10 | Alnylam Pharmaceuticals Inc. | $10 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2024 | |
| 2023-12-20 | Alnylam Pharmaceuticals Inc. | $3,039 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $1,228 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $793 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $654 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $648 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $362 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-04 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | $3,377 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | $1,467 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-12-01 | Alnylam Pharmaceuticals Inc. | $835 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-27 | Alnylam Pharmaceuticals Inc. | $1,944 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-11-27 | Alnylam Pharmaceuticals Inc. | $1,944 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $1,228 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $181 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $116 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $109 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $81 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-22 | Alnylam Pharmaceuticals Inc. | $54 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $1,895 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $786 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $333 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-08 | Alnylam Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $2,236 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $1,467 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $950 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-03 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $1,895 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $786 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $340 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $242 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-11-01 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-23 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-23 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $1,895 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $832 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $567 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $403 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $366 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $81 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-20 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $1,248 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $550 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $216 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $115 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-13 | Alnylam Pharmaceuticals Inc. | $90 | Research payment | Cash or cash equivalent | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $11,984 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $6,846 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $2,135 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,962 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,895 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,620 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,499 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $1,421 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $786 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $618 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $618 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $550 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $543 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $486 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $416 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $375 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $218 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $166 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $125 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-10-04 | Alnylam Pharmaceuticals Inc. | $45 | Research payment | Cash or cash equivalent | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) | 2023 | |
| 2023-09-29 | Alnylam Pharmaceuticals Inc. | $55 | Research payment | In-kind items and services | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihyperten | 2023 |
The latest 200 records of 754.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jacksonville, FL, county Duval County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Jacksonville, FL | County Duval County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 977,670 | 1,023,153 | 22,416,077 |
| Population, 2020 census P1 | 949,611 | 995,567 | 21,538,187 |
| Median age B01002 | 36.5 | 36.9 | 42.6 |
| Under 18 B01001 | 22.6% | 22.4% | 19.5% |
| 65 and over B01001 | 14.9% | 15.3% | 21.3% |
| Households B11001 | 394,370 | 415,128 | 8,752,810 |
| Foreign born B05002 | 12.5% | 12.2% | 21.9% |
| Median household income B19013 | $69,872 | $71,277 | $74,568 |
| Median family income B19113 | $85,182 | $87,532 | $89,891 |
| Per capita income B19301 | $38,879 | $40,568 | $42,609 |
| Poverty rate B17001 | 14.5% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.6% | 4.5% | 4.8% |
| Civilian labor force B23025 | 497,491 | 522,761 | 11,016,578 |
| Mean commute (minutes) B08013 | 24.1 | 24.1 | 28.0 |
| Bachelor's degree or higher B15003 | 33.2% | 34.4% | 34.1% |
| Housing units B25001 | 430,825 | 454,740 | 10,256,470 |
| Owner-occupied B25003 | 57.6% | 58.2% | 67.6% |
| Renters B25003 | 42.4% | 41.8% | 32.4% |
| Median home value B25077 | $293,700 | $303,500 | $359,000 |
| Median gross rent B25064 | $1,465 | $1,475 | $1,669 |
| White, not Hispanic B03002 | 46.8% | 48.4% | 50.4% |
| Black B03002 | 29.3% | 28.2% | 14.6% |
| Hispanic or Latino B03002 | 12.6% | 12.4% | 27.4% |
| Asian B03002 | 5.0% | 4.9% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jacksonville, FL.
Comments